We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Releases 83 Pages of Documents Defending and Explaining Alzheimer’s Drug Aduhelm’s Approval
FDA Releases 83 Pages of Documents Defending and Explaining Alzheimer’s Drug Aduhelm’s Approval
The FDA released two memos from officials and a long review document late Tuesday, shining new light on internal agency discussions over the past two years regarding Biogen’s Aduhelm, the very expensive new Alzheimer’s disease (AD) drug that’s caused a firestorm of controversy since the FDA approved it June 7 against the advice of its 11-member advisory panel, three of whom resigned in protest after the approval.